The DDI corpus: An annotated corpus with pharmacological substances and drug-drug interactions

Journal of Biomedical Informatics

Volumn 46, Issue 5, 2013, Pages 914-920

  Herrero Zazo, María ^a   Segura Bedmar, Isabel ^a   Martínez, Paloma ^a   Declerck, Thierry ^b  

^a UNIVERSIDAD CARLOS III DE MADRID   (Spain)

^b GERMAN RESEARCH CENTER FOR ARTIFICIAL INTELLIGENCE DFKI   (Germany)

Author keywords

Biomedical corpora; Drug interaction; Information extraction

Indexed keywords

AMOUNT OF INFORMATION; BIOMEDICAL CORPORA; BIOMEDICAL LITERATURE; DRUG-DRUG INTERACTIONS; HEALTH CARE PROFESSIONALS; INFORMATION EXTRACTION TECHNIQUES; NATURAL LANGUAGE PROCESSING; PHARMACOLOGICAL SUBSTANCES;

INFORMATION RETRIEVAL; LINGUISTICS; NATURAL LANGUAGE PROCESSING SYSTEMS; QUALITY CONTROL;

DRUG INTERACTIONS;

ALFUZOSIN; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANTIHYPERTENSIVE AGENT; CHLORTALIDONE; CLARITHROMYCIN; EFAVIRENZ; FENFLURAMINE; GREPAFLOXACIN; GUANETHIDINE; KETOCONAZOLE; METHYLDOPA; OMEPRAZOLE; RESERPINE; THEOBROMINE;

ARTICLE; BIOINFORMATICS; DATA BASE; DRUG ANTAGONISM; DRUG POTENTIATION; DRUG SURVEILLANCE PROGRAM; INFORMATION RETRIEVAL; MEDICAL LITERATURE; NATURAL LANGUAGE PROCESSING; PRIORITY JOURNAL; UNIFIED MEDICAL LANGUAGE SYSTEM;

BIOMEDICAL CORPORA; DRUG INTERACTION; INFORMATION EXTRACTION;

DRUG INTERACTIONS; GUIDELINES AS TOPIC;

EID: 84883756903     PISSN: 15320464     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jbi.2013.07.011     Document Type: Article

References (39)

1. Thamrongrattanarit A., Shafir M., Crivaro M., Borukhov B., Meteer M. What can NLP tell us about BioNLP?. Proceedings of the 2012 workshop on biomedical natural language processing 2012, 122-129. Association for Computational Linguistics.
2. Van Mulligen E.M., Fourrier-Reglat A., Gurwitz D., Molokhia M., Nieto A., Trifiro G., et al. The EU-ADR corpus: annotated drugs, diseases, targets, and their relationships. J Biomed Inform 2012, 45:879-884.
3. Aronson J. Communicating information about drug interactions. Br J Clin Pharmacol 2007, 63(6):637-639.
4. Jankel C., McMillan J., Martin B. Effect of drug interactions on outcomes of patients receiving warfarin or theophylline. Am J Health-Syst Pharm 1994, 51(5):661-666.
5. Wishart D.S., Knox C., Guo A.C., Shrivastava S., Hassanali M., Stothard P., et al. DrugBank: a comprehensive resource for in silico drug discovery and exploration. Nucleic Acids Res 2006, 34(suppl 1):D668-D672.
6. Baxter K., Stockely I.H. Stockley'sdrug interactions 2010, Pharmaceutical Press London, London. 9th ed.
7. Tatro D. Drug interaction facts 2010: the authority on drug interactions 2010, Wolters Kluwer Health, St. Louis MO.
8. Rodr íguez-Terol A., Caraballo M., Palma D., Santos-Ramos B., Molina T., Desongles T., et al. Quality of interaction database management systems. Farmacia Hospitalaria (English Edition) 2009, 33(3):134-146.
9. Paczynski R.P., Alexander G.C., Chinchilli V.M., Kruszewski S.P. Quality of evidence in drug compendia supporting off-label use of typical and atypical antipsychotic medications. Int J Risk Safety Med 2012, 24(3):137-146.
10. National Library of Medicine: Fact Sheet Medline. <>[Accessed 02.07.13]. http://www.nlm.nih.gov/pubs/factsheets/medline.html.
11. Stricker B.H., Psaty B.M. Detection, verification, and quantification of adverse drug reactions. BMJ: Br Med J 2004, 329(7456):44.
12. Hansten P.D. Drug interaction management. Pharm World Sci 2003, 25(3):94-97.
13. Segura-Bedmar I, Martinez P, Herrero-Zazo M. SemEval-2013 Task 9: extraction of drug-drug interactions from biomedical texts. In: Proceedings of the 7th international workshop on semantic evaluation (SemEval 2013); 2013.
14. Doan S., Kawazoe A., Conway M., Collier N. Towards role-based filtering of disease outbreak reports. J Biomed Inform 2009, 42(5):773-780.
15. Del éger L., Grouin C., Zweigenbaum P. Extracting medical information from narrative patient records: the case of medication-related information. J Am Med Infor Assoc 2010, 17(5):555-558.
16. Warrer P., Hansen E.H., Juhl-Jensen L., Aagaard L. Using text-mining techniques in electronic patient records to identify ADRs from medicine use. Br J Clin Pharmacol 2012, 73(5):674-684.
17. Xu R., Wang Q. Large-scale extraction of accurate drug-disease treatment pairs from biomedical literature for drug repurposing. BMC Bioinformatics 2013, 14(1):181.
18. Sutton N., Wojtulewicz L., Mehta N., Gonzalez G. Automatic approaches for gene-drug interaction extraction from biomedical text: corpus and comparative evaluation. Proceedings of the 2012 workshop on biomedical natural language processing 2012, 214-222. Association for Computational Linguistics.
19. Segura-Bedmar I., Martinez P., de Pablo-Sánchez C. Using a shallow linguistic kernel for drug-drug interaction extraction. J Biomed Inform 2011, 44(5):789-804.
20. Roberts A., Gaizauskas R., Hepple M., Demetriou G., Guo Y., Roberts I. Building a semantically annotated corpus of clinical texts. J Biomed Inform 2009, 42(5):950-966.
21. Rosario B., Hearst M.A. Classifying semantic relations in bioscience texts. Proceedings of the 42nd annual meeting on association for computational linguistics 2004, 430. Association for Computational Linguistics.
22. Gurulingappa H., Rajput A.M., Roberts A., Fluck J., Hofmann-Apitius M., Toldo L. Development of a benchmark corpus to support the automatic extraction of drug-related adverse effects from medical case reports. J Biomed Inform 2012, 45:885-892.
23. Alex B, Grover C, Haddow B, Kabadjov M, Klein E, Matthews M, et al. The ITI TXM corpora: tissue expressions and protein-protein interactions. In: Proceedings of LREC workshop on building and evaluating resources for biomedical text mining Citeseer, vol. 8. 2008. p. 11-8.
24. Boyce R., Gardner G., Harkema H. Using natural language processing to identify pharmacokinetic drug-drug interactions described in drug package inserts. Proceedings of the 2012 workshop on BioNLP 2012, 206-213. Association for Computational Linguistics.
25. Rubrichi S., Quaglini S. Summary of product characteristics content extraction for a safe drugs usage. J Biomed Inform 2012, 45(2):231-239.
26. Karnik S, Subhadarshini A, Wang Z, Rocha LM, Li L. Extraction of drug-drug interactions using all paths graph kernel. In: Proceedings of the 1st Challenge task on drug-drug interaction Extraction (DDIExtraction 2011); 2011. p. 83-88.
27. Uzuner Ö., Solti I., Cadag E. Extracting medication information from clinical text. J Am Med Inform Assoc 2010, 17(5):514-518.
28. Jagannathan V., Mullett C.J., Arbogast J.G., Halbritter K.A., Yellapragada D., Regulapati S., et al. Assessment of commercial NLP engines for medication information extraction from dictated clinical notes. Int J Med Inform 2009, 78(4):284.
29. Segura-Bedmar I, Martinez P, Sánchez-Cisneros D. The 1st DDIExtraction-2011 challenge task: extraction of drug-drug interactions from biomedical texts. In: Proceedings of the 1st Challenge task on drug-drug interaction Extraction (DDIExtraction 2011), vol. 2011. 2011. p. 1-9.
30. Aronson A.R. Effective mapping of biomedical text to the UMLS Metathesaurus: the MetaMap program. Proc AMIA symp 2001, 17. American Medical Informatics Association.
31. Pyysalo S., Airola A., Heimonen J., Björne J., Ginter F., Salakoski T. Comparative analysis of five protein-protein interaction corpora. BMC Bioinformatics 2008, 9(Suppl 3):S6.
32. Herrero-Zazo M, Segura-Bedmar I, Martínez P. Annotation issues in pharmacological texts. Procedia - Soc Behav Sci (in press).
33. Hochman M., Hochman S., Bor D., McCormick D. News media coverage of medication research: reporting pharmaceutical company funding and use of generic medication names. JAMA 2008, 300(13):1544-1550.
34. Steinman M.A., Chren M.-M. What'sin a name? Use of brand versus generic drug names in United States outpatient practice. J Gen Intern Med 2007, 22(5):645-648.
35. Bergk V., Haefeli W.E., Gasse C., Brenner H., Martin-Facklam M. Information deficits in the summary of product characteristics preclude an optimal management of drug interactions: a comparison with evidence from the literature. Eur J Clin Pharmacol 2005, 61(5-6):327-335.
36. Aronson J. Drug interactions-information education and the British National Formulary. Br J Clin Pharmacol 2004, 57(4):371-372.
37. Cohen J., et al. A coefficient of agreement for nominal scales. Educ Psych Meas 1960, 20(1):37-46.
38. Boring D. The development and adoption of nonproprietary, established, and proprietary names for pharmaceuticals. Drug Inf J 1997, 31(3):621-634.
39. Pustejovsky J., Stubbs A. Natural language annotation for machine learning. O'Reilly 2012.